Researcher’s Profile

Antonia R. Sepulveda, MD, PhD

Vice Chair for Translational Research
Director, Division of Gastrointestinal Pathology

Antonia R. Sepulveda MD, PhD is Professor and Vice Chair for Translational Research and Director of the Division of Gastrointestinal Pathology at Columbia University Medical Center. She is an expert in gastrointestinal pathology and molecular diagnostic pathology of cancer. Her clinical practice provides specialized gastrointestinal, biliary and pancreas pathology diagnostic services with integration of molecular testing utilizing genomics, epigenomics and specific tumor biomarkers for personalized cancer management and precision medicine of digestive organ cancers and pre-cancer conditions (esophageal cancer and Barrett's esophagus, gastric, colorectal, pancreas and biliary cancers and pre-cancer risk lesions). Dr. Sepulveda leadership is nationally recognized. She has been the lead co-chair for the Molecular testing guidelines for colorectal cancer, a combined initiative of the American Society for Clinical Pathology, College of American Pathologists Pathology and Laboratory Quality Center, Association for Molecular Pathology and the American Society of Clinical Oncology.

Dr. Sepulveda research is focused on an innovative integromics cancer research program exploring computationally generated networks integrating the molecular mechanisms and biomarkers of gastric and esophageal and pancreatic cancers and pre-cancer lesions. Through these cutting edge approaches Dr. Sepulveda hopes to define novel tumor types and regulatory pathways of cancer development and progression, and biomarkers for their diagnosis and therapy. Dr. Sepulveda has over 120 publications (original research, reviews, chapters and books).



Sepulveda JL, Gutierrez-Pajares JL, Luna A, Yao Y, Tobias JW, Thomas S, Woo Y, Georgio F, Komissarova E, Califano A, Wang TC, Sepulveda AR*. High Definition CpG Methylation of Novel Genes in Gastric Carcinogenesis Identified by Next Generation Sequencing. Modern Pathology. 2016 Feb;29(2):182-93.  PMID: 26769141

Hayakawa Y, Sethi N, Sepulveda AR, Bass AJ, Wang TC. Oesophageal adenocarcinoma and gastric cancer: should we mind the gap? Nat Rev Cancer. 2016 Apr 26;16(5):305-18. PMID: 27112208

Margolskee, E, Koehne de Gonzalez, A, Moreira RK, Lagana, SL, Sepulveda, AR, Remotti, H, Lefkowitch, JH, Bao, F, Salomao, M. Immunohistochemical and targeted mutational analysis of hepatocellular adenomas. Diagn Pathol. 2016 Mar 9;11(1):27.  PMID:26961851

Lee Y, Urbanska A, Hayakawa Y, Wang H, Andrew Au, Luna A, Chang W, Jin G, Bhagat G, Abrams J, Friedman R, Varro A, Wang K, Boyce M, Rustgi A, Sepulveda A, Quante M, Wang TW. Gastrin stimulates a Cholecystokinin-2-Receptor-expressing cardia progenitor cell and promotes progression of Barrett's-like esophagus. Oncotarget, 2017 Jan 3;8(1):203-214. PMID: 27448962

Del Portillo A, Lagana SM, Yao Y, Uehara T, Jhala N, Ganguly T, Nagy P, Gutierrez J, Luna A, Abrams J, Liu Y, Brand R, Sepulveda JL, Falk GW, Sepulveda AR*. Evaluation of Mutational Testing of Preneoplastic Barrett's Mucosa by Next-Generation Sequencing of Formalin-Fixed, Paraffin-Embedded Endoscopic Samples for Detection of Concurrent Dysplasia and Adenocarcinoma in Barrett's Esophagus. J Mol Diagn. 2015. pii: S1525-1578(15)00081-1. PMID:26068095. Press release June 8 2015.

Salomao M, Luna A, Sepulveda JL, Sepulveda AR. Mutational analysis by next generation sequencing of gastric type dysplasia occurring in hyperplastic polyps of the stomach: Mutations in gastric hyperplastic polyps. Exp Mol Pathol. 2015. 99(3):468-73. PMID: 26325218

Amaravadi RK, Hamilton K, Ma X, Piao S, Chapman P, Del Portillo A, Nathanson KL, Carlino MS, Long GV, Puzanov I, Xu X, Morrissette JD, Flaherty KT, Sosman JA, Goodman G, McArthur G, Rustgi A, Metz D, Schuchter LM, Sepulveda AR. Prolonged BRAF inhibitor treatment can lead to the development of multiple gastrointestinal polyps. Clin Cancer Res. 2015. 21(23):5215-21. PMID:26202952

Hayakawa Y, Ariyama H, Stancikova J, Asfaha S, Muley A, Shibata W, Wang H, Dubeykovskaya ZA, Westphalen CB, Renz BW, Tailor Y, Nagar K, Tomita H, Hara A, Sepulveda AR, Setlik W, Gershon MD, Ding L, Subhrajit S, Konieczny SF, Worthley DL, Korinek V, Wang TC. CXCL12/CXCR4-dependent perivascular niche regulates quiescent Mist1+ gastric stem cells and contributes to cancer development. Cancer Cell. 14;28(6):800-14. 2015. PMID:26585400

Molecular and histologic considerations in the assessment of serrated polyps. Yang HM, Mitchell JM, Sepulveda JL, Sepulveda AR*. Arch Pathol Lab Med. 2015 Jun;139(6):730-41. PMID: 26030242

New Insights into the Genetics of Fetal Megacystis: ACTG2 Mutations, Encoding γ-2 Smooth Muscle Actin in Megacystis Microcolon Intestinal Hypoperistalsis Syndrome (Berdon Syndrome). Tuzovic L, Tang S, Miller RS, Rohena L, Shahmirzadi L, Gonzalez K, Li X, LeDuc CA, Guo J, Wilson A, Mills A, Glassberg K, Rotterdam H, Sepulveda AR, Zeng W, Chung WK, Anyane-Yeboa K. Fetal Diagn Ther. 2015. PMID: 25998219

Lagana S, Hsiao S, Bao F, Sepulveda A, Moreira R, Lefkowitch J, Remotti H. HepPar-1 and Arginase-1 in small intestinal and ampullary adenocarcinoma. Arch Pathol Lab Med. 2015 Jun;139(6):791-5. doi: 10.5858/arpa.2013-0249-OA. PMID: 26030248

Zutter MM, Bloom KJ, Cheng L, Hagemann IS, Kaufman JH, Krasinskas AM, Lazar AJ, Leonard DG, Lindeman NI, Moyer AM, Nikiforova MN, Nowak JA, Pfeifer JD, Sepulveda AR, Willis JE, Yohe SL. The Cancer Genomics Resource List 2014. Arch Pathol Lab Med. PMID: 25436904.

Frank R, Li S, Ahmad NA, Sepulveda AR, Jhala NC. Mesothelin expression in pancreatic mucinous cysts. Am J Clin Pathol. 142(3):313-9, 2014. PMID: 25125620.

Fasanella KE, Bista RK, Staton K, Rizvi S, Uttam S, Zhao C, Sepulveda A, Brand RE, McGrath K, Liu Y. Nuclear Nano-architecture Markers of Gastric Cardia and Upper Squamous Esophagus Detect Esophageal Cancer "Field Effect". J Cancer. 4(8):626-634, 2013. PMID: 24155774.

Sohal DP, Mykulowycz K, Uehara T, Teitelbaum UR, Damjanov N, Giantonio BJ, Carberry M, Wissel P, Jacobs-Small M, O'Dwyer PJ, Sepulveda A, Sun W. A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma. Ann Oncol. (12):3061-5, 2013. PMID: 24146220.

Kim J, Hoffman JP, Alpaugh RK, Rhim AD, Reichert M, Stanger BZ, Furth EE, Sepulveda AR, Yuan CX, Won KJ, Donahue G, Sands J, Gumbs AA, Zaret KS. An iPSC line from human pancreatic ductal adenocarcinoma undergoes early to invasive stages of pancreatic cancer progression. Cell Rep. 3 (6):2088-2099, 2013. PMID: 23791528.